A compound of Formula I ##STR00001## wherein X.sup.1, X.sup.2, X.sup.3, and X.sup.4 are independently selected from the group consisting of CR.sup.A and N; X.sup.5, X.sup.6, X.sup.7, and X.sup.8 are independently selected from the group consisting of CR.sup.B and N; Y is selected from the group consisting of NR.sup.2, O, S, CR.sup.3R.sup.4, SiR.sup.3R.sup.4 and GeR.sup.3R.sup.4; Z is selected from the group consisting of B, SiR.sup.5, and GeR.sup.6;
wherein R.sup.A and R.sup.B represent mono to the maximum allowable substitution, or no substitution; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, silyl, aryl, heteroaryl, acyl, nitrile, and combinations thereof. The compounds of Formula I will have at least one of R.sup.A, R.sup.B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 that comprises a structure selected from the group consisting of: ##STR00002## wherein X is selected from the group consisting of NR.sup.7, O, S and Se; and X.sup.9-X.sup.41 are each independently selected from the group consisting of C and N; and at least one of X.sup.34-X.sup.41 is N. We also describe an OLED comprising an organic layer that includes a compound of Formula I and a consumer product that includes the OLED.

The present invention provides a compound comprising a moiety of the formula: (I) where said moiety of formula I is a radical, a cation, or a radical dication; Y.sup.1, Y.sup.2, Y.sup.3, R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.2d, R.sup.3a, R.sup.3b, R.sup.3c, and R.sup.3d are as defined herein. Compounds containing a moiety of Formula I are useful in a wide variety of applications including, but not limited to, as photocatalysts, use in OLEDs, in electronic components, etc. As an organic-based photocatalysts, compounds containing a moiety of Formula I are activated by a relatively low energy electromagnetic wavelength, e.g., wavelength of 600 nm or greater. Furthermore, compounds of the invention can be used as both photoreduction catalysts and photooxidation catalysts.

##STR00001##

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

An object of the present invention is to provide a kit and a method capable of achieving high-precision measurement of a measurement target substance in a biological sample in a wide concentration range from a low concentration to a high concentration by sufficiently avoiding the influence of antibodies such as anti-serum albumin antibody present in blood. According to the present invention, there is provided a kit for measuring a measurement target substance in a biological sample, the kit including: a labeled particle having a first binding substance capable of binding to the measurement target substance and having a first blocking agent; and a substrate having a second binding substance capable of binding to any one of the measurement target substance or the first binding substance and having a second blocking agent, in which the labeled particle is a luminescent labeled particle containing at least one kind of compound represented by Formula (1) and a particle, and the first blocking agent and the second blocking agent are different from each other. ##STR00001## Each symbol in Formula (1) has the meaning described in the present specification.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of Cbl-b, and the treatment of Cbl-b-mediated disorders.

The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.

The present specification relates to a compound, and a color conversion film, a backlight unit, and a display device, including the same.

The present specification relates to a compound, and a color conversion film, a backlight unit and a display apparatus including the same.

Described herein are boron-containing precursor compounds, and compositions and methods comprising same, for forming boron-containing films. In one aspect, the film is deposited from at least one precursor having the following Formula I or II described herein. ##STR00001##

The present disclosure relates to Near-infrared fluorescent indicators for lysosomes and application thereof. These indicators are composed of lipophilic NIR BODIPY derivatives and ionizable bis-tertiary amine moiety, which enable the formation of a transient amphiphilic state in acidic environments specifically. This structural feature affords accurate lysosomal membrane targeting ability at nanomole staining concentration.